Zurcher Kantonalbank (Zurich Cantonalbank) has added 282,084 shares of $BIIB to their portfolio, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 09-30-2025 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $BIIB.
BIOGEN Hedge Fund Activity
We have seen 433 institutional investors add shares of BIOGEN stock to their portfolio, and 414 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 3,424,470 shares (+840.9%) to their portfolio in Q2 2025, for an estimated $430,079,187
- BLACKROCK, INC. added 1,208,486 shares (+8.9%) to their portfolio in Q3 2025, for an estimated $169,284,718
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,135,207 shares (+65.1%) to their portfolio in Q3 2025, for an estimated $159,019,796
- PRIMECAP MANAGEMENT CO/CA/ removed 847,425 shares (-5.4%) from their portfolio in Q3 2025, for an estimated $118,707,294
- AMUNDI removed 736,150 shares (-55.9%) from their portfolio in Q2 2025, for an estimated $92,453,078
- MARSHALL WACE, LLP added 721,706 shares (+434.9%) to their portfolio in Q3 2025, for an estimated $101,096,576
- QUBE RESEARCH & TECHNOLOGIES LTD removed 621,702 shares (-83.6%) from their portfolio in Q3 2025, for an estimated $87,088,016
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIOGEN Insider Trading Activity
BIOGEN insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 4,323 shares for an estimated $549,552.
- RACHID IZZAR (Head of Global Product Strat.) sold 2,223 shares for an estimated $300,105
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIOGEN Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 11/06/2025
- RBC Capital issued a "Outperform" rating on 10/31/2025
- Jefferies issued a "Buy" rating on 09/25/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/01/2025
To track analyst ratings and price targets for BIOGEN, check out Quiver Quantitative's $BIIB forecast page.
BIOGEN Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 9 analysts offer price targets for $BIIB in the last 6 months, with a median target of $157.0.
Here are some recent targets:
- Paul Matteis from Stifel set a target price of $202.0 on 11/06/2025
- William Pickering from Bernstein set a target price of $157.0 on 11/03/2025
- Brian Abrahams from RBC Capital set a target price of $210.0 on 10/31/2025
- Matthew Harrison from Morgan Stanley set a target price of $149.0 on 10/10/2025
- Andrew Tsai from Jefferies set a target price of $190.0 on 09/25/2025
- David Amsellem from Piper Sandler set a target price of $118.0 on 08/14/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $194.0 on 08/01/2025
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $BIIB ticker page for more data.
